IRIS
MAIO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.600
EU - Europa 16.089
AS - Asia 11.991
SA - Sud America 3.865
Continente sconosciuto - Info sul continente non disponibili 1.257
AF - Africa 496
OC - Oceania 59
Totale 59.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.096
SG - Singapore 4.568
IT - Italia 3.791
RU - Federazione Russa 3.544
BR - Brasile 3.176
IE - Irlanda 2.525
CN - Cina 2.524
GB - Regno Unito 2.053
VN - Vietnam 1.934
FR - Francia 1.304
HK - Hong Kong 1.179
UA - Ucraina 787
SE - Svezia 616
DE - Germania 482
BD - Bangladesh 392
FI - Finlandia 301
IN - India 294
AR - Argentina 252
ZA - Sudafrica 245
KR - Corea 243
CA - Canada 211
ES - Italia 193
MX - Messico 134
NL - Olanda 130
EC - Ecuador 129
ID - Indonesia 116
IQ - Iraq 107
CO - Colombia 80
AT - Austria 78
TR - Turchia 74
JP - Giappone 62
VE - Venezuela 57
SA - Arabia Saudita 56
AU - Australia 55
PK - Pakistan 54
CL - Cile 51
PL - Polonia 48
PY - Paraguay 48
KE - Kenya 39
MA - Marocco 39
UZ - Uzbekistan 39
AE - Emirati Arabi Uniti 33
AZ - Azerbaigian 32
JM - Giamaica 32
MY - Malesia 32
EG - Egitto 31
NG - Nigeria 30
TN - Tunisia 30
UY - Uruguay 27
DZ - Algeria 26
PE - Perù 26
CZ - Repubblica Ceca 25
NP - Nepal 24
LT - Lituania 22
CH - Svizzera 21
IL - Israele 21
AL - Albania 20
KZ - Kazakistan 20
BE - Belgio 18
BO - Bolivia 18
JO - Giordania 18
PA - Panama 18
CR - Costa Rica 17
PT - Portogallo 17
DO - Repubblica Dominicana 16
OM - Oman 16
GR - Grecia 15
HN - Honduras 15
LB - Libano 15
PH - Filippine 15
BG - Bulgaria 14
IR - Iran 14
CI - Costa d'Avorio 12
KG - Kirghizistan 12
ET - Etiopia 11
TW - Taiwan 11
HU - Ungheria 10
SK - Slovacchia (Repubblica Slovacca) 10
TH - Thailandia 10
TT - Trinidad e Tobago 10
XK - ???statistics.table.value.countryCode.XK??? 10
AM - Armenia 9
BH - Bahrain 9
KW - Kuwait 9
NI - Nicaragua 9
NO - Norvegia 9
BY - Bielorussia 8
DK - Danimarca 8
LV - Lettonia 8
PS - Palestinian Territory 8
SV - El Salvador 8
BB - Barbados 7
KH - Cambogia 7
RO - Romania 7
AO - Angola 6
GT - Guatemala 6
LK - Sri Lanka 6
SN - Senegal 6
SY - Repubblica araba siriana 6
BA - Bosnia-Erzegovina 5
Totale 58.021
Salva come PNG Salva come JPEG
Città #
Fairfield 3.020
Dallas 2.943
Dublin 2.520
Singapore 2.100
Ashburn 1.904
Southend 1.639
Woodbridge 1.447
San Jose 1.310
Milan 1.271
Wilmington 1.144
Hong Kong 1.142
Seattle 1.141
Houston 1.137
Cambridge 1.041
Council Bluffs 926
Moscow 917
Beijing 856
Santa Clara 815
Jacksonville 758
Ho Chi Minh City 616
Princeton 536
Rome 438
Siena 415
Lauterbourg 411
The Dalles 404
Ann Arbor 402
Hefei 378
Hanoi 368
San Mateo 359
Los Angeles 325
New York 286
Dong Ket 280
São Paulo 249
Helsinki 239
Seoul 224
Dearborn 199
San Diego 199
Johannesburg 192
Chandler 171
Buffalo 154
Florence 148
Redondo Beach 135
Málaga 131
Shanghai 129
Figino 125
Chicago 102
London 99
Rio de Janeiro 95
Nuremberg 90
San Francisco 82
Orem 78
Amsterdam 77
Turin 75
Da Nang 74
Munich 65
Columbus 64
Brooklyn 63
Phoenix 63
Haiphong 62
Brasília 59
Toronto 57
Belo Horizonte 56
Tokyo 56
Salvador 55
Dhaka 54
Frankfurt am Main 54
Curitiba 52
Naples 52
Bar Harbor 51
Montreal 50
Bengaluru 49
Boardman 49
Denver 48
Guayaquil 47
Nanjing 47
Delhi 44
Stockholm 44
Chennai 43
Guangzhou 43
Porto Alegre 43
Campinas 42
Norwalk 42
Vienna 41
Bologna 40
Guarulhos 40
Atlanta 39
Lappeenranta 38
Tashkent 36
Warsaw 36
Washington 35
Boston 34
Manchester 34
Mexico City 34
Palermo 34
Quito 34
Baghdad 33
Goiânia 32
Catania 31
Buenos Aires 30
Hải Dương 30
Totale 38.401
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 514
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 359
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 337
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 331
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade 300
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 277
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 272
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 265
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 263
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 259
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 256
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 255
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 252
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 251
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 250
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 244
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 241
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 238
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 237
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 237
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 236
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 236
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 230
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 230
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 226
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 222
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 216
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 216
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy 216
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 214
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 214
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 213
Biology and clinical applications of CD40 in cancer treatment 211
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 210
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 209
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 208
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial 208
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 207
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 207
Biomolecular strategies for therapeutic intervention in cancer 206
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 206
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma 201
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 201
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 199
A novel microRNA signature for the detection of melanoma by liquid biopsy 199
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability 199
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 198
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study 197
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 196
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 195
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma 195
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 194
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial 194
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma 194
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 192
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 192
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 191
Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study 191
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 191
Epigenetically-regulated Tumor-Associated Antigens in melanoma 189
Perspectives on the role of “-Omics” in predicting response to immunotherapy 186
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" 186
Immunotherapy targeting immune check-point(s) in brain metastases 186
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 185
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 184
Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma 183
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? 182
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 182
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy 182
Active immunization of melanoma patients with IL-2- or IL-4-transduced allogeneic melanoma cells 181
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 180
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody 180
Predictors of responses to immune checkpoint blockade in advanced melanoma 180
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study 180
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 179
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 179
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 176
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 176
The role of BRAF V600 mutation in melanoma 175
Nivolumab in previously untreated melanoma without BRAF mutation 175
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 174
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications 173
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 173
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients 173
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001 172
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response 171
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011” 171
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 170
Epigenetic drugs as immunomodulators for combination therapies in solid tumors 170
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 170
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study 169
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells 169
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells 168
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 168
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 168
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009 167
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma 165
Towards the introduction of the Immunoscore in the classification of malignant tumors 165
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010" 165
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) 165
Totale 20.890
Salva come PNG Salva come JPEG
Categoria #
all - tutte 212.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 212.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.943 0 0 385 98 44 162 121 153 224 525 373 858
2022/20233.141 409 174 644 401 76 696 86 123 156 143 172 61
2023/20243.551 92 77 269 88 84 1.004 1.218 110 62 37 64 446
2024/20258.496 337 379 449 487 759 329 119 298 956 1.045 1.121 2.217
2025/202622.982 1.491 3.042 2.578 3.326 3.577 650 2.302 782 774 1.084 865 2.511
2026/20273.138 1.496 726 916 0 0 0 0 0 0 0 0 0
Totale 59.357